Nemolizumab Monotherapy Successful in Prurigo Nodularis Patients Becoming Itch-Free

New late-breaking phase 3 data showed success with nemolizumab, an investigational drug designed for targeting IL-31 signaling and aimed at the underlying causes of the condition.

Related Keywords

Singapore ,Clin Pharmacol ,Dermatol Venereol ,Nemolizumab Monotherapy ,World Congress ,Late Breaking Phase ,Published July ,Eur Acad Dermatol ,Expert Rev Clin ,